Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Payables (2016 - 2025)

Adma Biologics (ADMA) has disclosed Payables for 14 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 11.38% year-over-year to $22.5 million, compared with a TTM value of $22.5 million through Dec 2025, up 11.38%, and an annual FY2025 reading of $22.5 million, up 11.38% over the prior year.
  • Payables was $22.5 million for Q4 2025 at Adma Biologics, down from $24.0 million in the prior quarter.
  • Across five years, Payables topped out at $112.2 million in Q1 2021 and bottomed at $6.2 million in Q2 2021.
  • Average Payables over 5 years is $21.4 million, with a median of $15.8 million recorded in 2023.
  • Peak annual rise in Payables hit 1125.41% in 2021, while the deepest fall reached 92.74% in 2021.
  • Year by year, Payables stood at $12.4 million in 2021, then grew by 6.43% to $13.2 million in 2022, then grew by 18.38% to $15.7 million in 2023, then rose by 29.11% to $20.2 million in 2024, then grew by 11.38% to $22.5 million in 2025.
  • Business Quant data shows Payables for ADMA at $22.5 million in Q4 2025, $24.0 million in Q3 2025, and $29.8 million in Q2 2025.